Stock GWYNF GENOWAY
Add to a list
To use this feature you must be a member
Log inSign up

Financials genOway OTC Markets

Equities

GWYNF

FR0004053510

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 		5-day change 1st Jan Change
- USD -.--% Intraday chart for genOway -.--% -.--%
2023 GenOway: sharp rise, broker initiates buy recommendation CF
2023 GENOWAY : Euroland initiates buy coverage CF

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 12.6 7.32 21.45 37.85 35.3 40.59
Enterprise Value (EV) 1 14.21 12.25 29.49 43.07 39.45 43.56
P/E ratio 22.1 x - - - - -
Yield - - - - - -
Capitalization / Revenue 0.84 x 0.52 x 1.32 x 1.93 x 1.67 x 1.53 x
EV / Revenue 0.95 x 0.88 x 1.81 x 2.2 x 1.87 x 1.64 x
EV / EBITDA 9.96 x 22.9 x 34.9 x 99.8 x 13.1 x 7.49 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 1.6 x - - - - -
Nbr of stocks (in thousands) 5,832 5,856 6,919 8,824 8,824 8,824
Reference price 2 2.160 1.250 3.100 4.290 4.000 4.600
Announcement Date 4/30/19 5/4/20 4/28/22 4/28/22 4/28/23 5/1/24
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 14.95 13.99 16.29 19.59 21.09 26.51
EBITDA 1 1.427 0.5342 0.844 0.4318 3.006 5.815
EBIT 1 0.5798 -0.6461 -0.3771 -0.7893 0.4886 1.565
Operating Margin 3.88% -4.62% -2.32% -4.03% 2.32% 5.9%
Earnings before Tax (EBT) 1 0.5492 -0.9732 -0.6108 -0.3519 0.7589 1.548
Net income 1 0.5716 -1.036 -0.6873 -0.3226 0.7778 1.568
Net margin 3.82% -7.41% -4.22% -1.65% 3.69% 5.91%
EPS 2 0.0978 - - - - -
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/30/19 5/4/20 4/28/22 4/28/22 4/28/23 5/1/24
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 1.62 4.93 8.05 5.22 4.16 2.97
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.133 x 9.228 x 9.532 x 12.09 x 1.383 x 0.5113 x
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) 7.58% -14.1% -8.68% -2.72% 5.04% 9.35%
ROA (Net income/ Total Assets) 1.97% -2.08% -1.01% -1.64% 0.93% 3.02%
Assets 1 29.07 49.84 68.13 19.69 83.51 51.89
Book Value Per Share 2 1.350 - - - - -
Cash Flow per Share 2 0.5200 - - - - -
Capex - - - - - -
Capex / Sales - - - - - -
Announcement Date 4/30/19 5/4/20 4/28/22 4/28/22 4/28/23 5/1/24
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+22.10% 46.55B
LONZA GROUP AG Stock Lonza Group AG
+46.45% 41.84B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.12% 40.84B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+36.10% 32.95B
CELLTRION, INC. Stock Celltrion, Inc.
-6.30% 28.27B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+18.71% 27.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+46.15% 14.26B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+44.52% 13.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.19% 12.18B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALGEN Stock
  4. GWYNF Stock
  5. Financials genOway